Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 4;13:3833. doi: 10.1038/s41467-022-31155-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a EIF4A2 mRNA expression in different subtypes of AML as compared to healthy bone marrow control, on the basis of data from Microarray Innovations in Leukemia (MILE) study (GSE13204). Data are presented as mean ± SD, two-tailed Student’s t test. b EIF4A2 transcript level in LSC-enriched (n = 138) vs LSC-depleted (n = 89) subsets from 78 AML patient samples (GSE76008). Average fold change of EIF4A2 expression in LSC-enriched over LSC-depleted subsets is indicated in the figure. Data are presented as mean ± SD, two-tailed Student’s t test. c EIF4A2 protein level as assessed proteomics analysis in functionally defined LSC and non-LSC populations from 5 AML patient samples (PXD008307). Data are presented as mean ± SEM, two-tailed Student’s t test. d Gene expression data (GSE35008) from sorted AML bone marrow samples were compared with data from healthy controls and revealed significantly increased EIF4A2 expression in AML LT-HSCs (Lin^-CD34 + CD38^-CD90 + , AML with normal karyotype, n = 3) compared with healthy control (n = 4). Data are presented as mean ± SD, two-tailed Student’s t test. e WB validation of EIF4A2 knockdown in GFP + transduced HL60 cells. f, g Flow cytometric evaluation of myeloid differentiation (f) and apoptosis (g) following EIF4A2 knockdown in primary AML cells. n = 3, mean ± SD, two-tailed Student’s t test. h–j Colony formation capacity following EIF4A2 knockdown in 3 AML samples. n = 3, mean ± SD, two-tailed Student’s t test. k, l Representative flow cytometry plots (k) and quantification (l) of AML engraftment (#007) after 8 weeks in bone marrow. n = 6 for each group. Shown is the percentage of human (CD45⁺) myeloid cells (CD33⁺) found in bone marrow. Data are presented as mean ± SD, two-tailed Student’s t test. Source data are provided as a Source Data file.